izeltabart tapatansine

**Izeltabart tapatansine (IMGC936)** is an investigational antibody-drug conjugate (ADC) comprising a humanized monoclonal antibody (izeltabart, MGA021) targeting **ADAM9** (a disintegrin and metalloproteinase 9), conjugated via a stable peptide linker to the maytansinoid payload **DM21**, a tubulin inhibitor. Developed originally by **ImmunoGen** in collaboration with **MacroGenics**, it was designed for **intravenous** administration to treat **ADAM9-expressing solid tumors**, leveraging the antibody's high affinity and YTE mutation for improved pharmacokinetics. ADAM9 is overexpressed in tumors like **non-small cell lung cancer (NSCLC)** (62%), **triple-negative breast cancer (TNBC)** (65%), **gastric cancer** (73%), and **pancreatic cancer** (85%), promoting tumor progression, migration, and metastasis; the ADC internalizes into target cells, releasing the payload to disrupt microtubule dynamics and induce cell death.[1][2][4][7][12]

Other names

Anti-ADAM9 ADCAnti-ADAM-9 ADCAnti-ADAM 9 ADC